Stay updated on AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial
Sign up to get notified when there's something new on the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page.

Latest updates to the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page
- Check6 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, indicating a new release of the page or its underlying tooling. This update does not alter the visible study details.SummaryDifference0.0%

- Check13 days agoChange DetectedA new investigator/location entry Tel Litwinsky, Israel was added, along with a new publication citation related to ATTR-CM attributes. A location entry Qiryat Krinitzi, Israel was removed.SummaryDifference0.1%

- Check20 days agoChange DetectedQiryat Krinitzi, Israel was added to the study sites and Tel Litwinsky, Israel was removed. The page revision was updated to v3.6.6.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded a funding note indicating a 2018 U.S. NIH grant/contract. Added a forthcoming publication citation for Pfister R et al., 'ACO-SWITCH: Rationale and Design of a Phase 4 Study Evaluating Serum Transthyretin in ATTR-CM After Switching from Tafamidis to Acoramidis' in Cardiol Ther, 2026 Aug 20.SummaryDifference0.1%

- Check41 days agoChange DetectedAn additional publication citation with a long author list and the plain-language summary of acoramidis was added to the Publications section. A new revision tag (Revision: v3.6.5) was introduced and the previous tag (Revision: v3.6.4) removed, reflecting an update to the study's documentation.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded a new publication citation to the Publications section for a 2026 JAMA Cardiology study that analyzes acoramidis (AG10) effects on heart failure-related health status in ATTR-CM. This external analysis expands the evidentiary context of the trial’s investigational drug.SummaryDifference0.0%

Stay in the know with updates to AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page.